Project Grant R43NS103596

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $423,500 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to the Augusta University Research Institute, Inc. The objective is to develop and evaluate engineered exosomes carrying neuron-targeting peptides and a therapeutic protein (neuroglobin) for treating ischemic stroke. The research will: 1) characterize the engineered exosomes and assess their...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $755,749 to Duquesne University to develop engineered extracellular vesicles (EVs) for delivering mitochondria and therapeutic proteins to the blood-brain barrier (BBB) to protect it from damage caused by ischemic stroke. The goal is to co-deliver innate EV mitochondria and the...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) provides $1,150,417 to Gentibio, Inc. to develop a novel allogeneic engineered tissue regulatory T cell (EngrTreg) therapy for the treatment of acute ischemic stroke. The key products or services to be delivered include: Development of an "off-the-shelf" EngrTreg therapy that leverages...

This $274,218.64 Project Grant from the National Institutes of Health's National Institute of Neurological Disorders and Stroke to Brandeis University will support research into the mechanisms underlying exosome release from neurons. The grant aims to determine how exosomes are generated from the endosomal system in neurons and explore neuronal exosome and endosome biology in an animal model. The grantee will manipulate the ESCRT and MUNC13-4/RAB11 pathways to investigate endosomal dynamics...

This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), is supporting research to develop mitochondrial-targeting exosomes (MTEs) containing anti-inflammatory microRNAs (MTE-miRNAs) to treat neuroinflammation. The $469,500 award to Michigan Technological University aims to restore mitochondrial function, reduce oxidative stress,...

The University of Pittsburgh has been awarded a $428,400 federal Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to study the role of the astrocytic sodium bicarbonate transporter NBCE1 in regulating blood-brain barrier (BBB) integrity during ischemic stroke. The project aims to investigate whether pathological activation of NBCE1 in astrocyte endfeet contributes to...

The U.S. National Institute of Neurological Disorders and Stroke (NINDS) awarded a $125,685 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to The Leland Stanford Junior University (Stanford University). The funding will support the development of an injectable hydrogel with an integrated urokinase plasminogen activator (uPA) motif and plasmid DNA (pDNA) platelet-derived growth factor B (PDGFB)-lipoplexes to be loaded into the...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $429,000 project grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to Oregon Health & Science University (OHSU). The purpose of this 2-year grant is to investigate mechanisms of white matter injury following an ischemic stroke and evaluate the neuroprotective effects of the CK2 inhibitor CX-4945 on preserving white matter function. The project aims to utilize...

This Project Grant award of $1,489,811.00 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is focused on validating an ex vivo gene correction strategy and ensuring the safety, therapeutic efficacy, and delivery of an autologous cell replacement therapy for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). The award aims to...

This federal Project Grant award of $399,997 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the development of neural exosome therapeutics for treating opioid-induced brain hypoxia injuries. The grantee, Aruna Bio Inc., is leveraging its patented neural exosome platform technology, AB126, to demonstrate the anti-inflammatory and neuroprotective effects of these exosomes in preclinical models of opioid-induced brain...